LYEL Lyell Immunopharma, Inc
Price Chart
Executive Summary
Lyell Immunopharma announced updated safety data from its Phase 1 trial of LYL273 in metastatic colorectal cancer, showing GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% to 10%. The trial was amended to a Phase 1/2 design enabling a potential pivotal single-arm Phase 2 trial, with an End-of-Phase 1 FDA meeting and additional clinical data expected in H2 2026.
Actionable Insight
The substantial safety improvement and trial amendment to a registrational path are significant catalysts. Monitor for additional Phase 1 data and End-of-Phase 1 FDA meeting in H2 2026, which could de-risk LYL273's regulatory pathway and support a pivotal trial start.
Key Facts
- GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% (without prophylaxis, N=9) to 10% (with prophylaxis, N=10).
- No Grade ≥3 CRS or ICANS observed in patients receiving GI prophylaxis.
- Maximum tolerated dose has not yet been determined; dose escalation continues.
- Phase 1 trial amended to Phase 1/2 design (CARABINER) enabling seamless expansion into a potential pivotal single-arm Phase 2 trial.
- New cohorts added: second-line cohort and combination with radiotherapy; up to 60 patients expected across new cohorts.
- End-of-Phase 1 FDA meeting and additional Phase 1 clinical data expected in H2 2026.
- LYL273 has FDA Fast Track designation for mCRC.
- Previously reported 50% overall response rate across Dose Levels 1 and 2 (data cutoff Oct 28, 2025) in 3L+ mCRC.
Financial Impact
No financial figures disclosed; early-stage clinical data with no revenue or deal value.
Risk Factors
- Maximum tolerated dose not yet determined; dose escalation could reveal unexpected toxicity.
- Phase 2 regulatory alignment with FDA is pending and not guaranteed.
- Small sample size (N=19) limits statistical reliability of safety and efficacy data.
- Solid tumor CAR-T remains a challenging field with high historical failure rates.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307886 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Press Release
| $13.32 awaiting T+20 | awaiting T+20 | — | $13.50 (+1.39%) |
|
Jun 8, 2026
5d ago
|
Press Release
| $11.94 awaiting T+20 | awaiting T+20 | — | $13.50 (+13.11%) |
|
Jun 4, 2026
8d ago
|
Press Release
| $13.02 awaiting T+20 | awaiting T+20 | — | $13.50 (+3.73%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $13.50 (−40.32%) |
|
Apr 15, 2026
8w ago
|
EFFECT
| $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $13.50 (−43.37%) |
|
Apr 3, 2026
10w ago
|
S-3
| $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $13.50 (−37.76%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $13.50 (−36.47%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $25.50 $21.78 | ▼ −14.59% | ▼ −11.78% | $13.50 (−47.06%) |
|
Mar 6, 2026
14w ago
|
Insider Cluster
| $22.46 $21.69 | ▼ −3.43% | ▼ −1.38% | $13.50 (−39.89%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $24.10 $19.29 | ▼ −19.96% | ▼ −12.02% | $13.50 (−43.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access